These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15154823)

  • 41. EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
    EUROmediCAT Steering Group
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():3-7. PubMed ID: 26395593
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessing and managing the hazards and risks of chemicals in the real world--the role of the EU's REACH proposal in future regulation of chemicals.
    Warhurst AM
    Environ Int; 2006 Dec; 32(8):1033-42. PubMed ID: 17055580
    [No Abstract]   [Full Text] [Related]  

  • 43. European perspective on risk management and drug safety.
    Raine J; Wise L; Blackburn S; Eichler HG; Breckenridge A
    Clin Pharmacol Ther; 2011 May; 89(5):650-4. PubMed ID: 21512526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
    Ghosh R; Lewis D
    Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
    Härmark L; Raine J; Leufkens H; Edwards IR; Moretti U; Sarinic VM; Kant A
    Drug Saf; 2016 Oct; 39(10):883-90. PubMed ID: 27379887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PARENT joint action: increasing the added value of patient registries in a cross-border setting.
    Meglič M; Doupi P; Pristaš I; Skalkidis Y; Zaletel M; Orel A
    Stud Health Technol Inform; 2013; 192():1161. PubMed ID: 23920935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stakeholder consultations and opportunities for integrating socio-behavioural factors into the pesticide risk analysis process.
    Calliera M; Marchis A; Sacchettini G; Capri E
    Environ Sci Pollut Res Int; 2016 Feb; 23(3):2937-47. PubMed ID: 26498808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. European experience in chemicals management: integrating science into policy.
    Christensen FM; Eisenreich SJ; Rasmussen K; Sintes JR; Sokull-Kluettgen B; Van de Plassche EJ
    Environ Sci Technol; 2011 Jan; 45(1):80-9. PubMed ID: 20958022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beyond REACH: roadblocks and shortcuts en route to integrated risk assessment and management of chemicals.
    Assmuth T; Hildén M; Craye M
    Sci Total Environ; 2010 Aug; 408(18):3954-63. PubMed ID: 20347473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.
    Essink SCM; Zomerdijk IM; Straus SMJM; Gardarsdottir H; De Bruin ML
    Drug Saf; 2023 Oct; 46(10):1007-1020. PubMed ID: 37658281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Experimental testing of centrally authorised medicinal products. The CAP programme].
    Giess S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1169-72. PubMed ID: 25159224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perspective of Saudi undergraduate pharmacy students on pharmacovigilance and adverse drug reaction reporting: A National Survey.
    Alkayyal N; Cheema E; Hadi MA
    Curr Pharm Teach Learn; 2017 Sep; 9(5):779-785. PubMed ID: 29233304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 56. REACH: next step to a sound chemicals management.
    Van der Wielen A
    J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S2-6. PubMed ID: 17637708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The future of pharmacovigilance: a personal view.
    Edwards IR
    Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624
    [No Abstract]   [Full Text] [Related]  

  • 58. European Union: the seventh Framework Programme resuscitates public health research.
    Saracci R
    Eur J Public Health; 2007 Jun; 17(3):237. PubMed ID: 17452391
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hygiene and Public Health - Significance in Medicine and Society].
    Exner M; Wiesmüller GA
    Gesundheitswesen; 2015 Jul; 77(7):488-95. PubMed ID: 26227382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Terminology services--an example of knowledge management in public health.
    Balkányi L
    Euro Surveill; 2007 May; 12(5):E070531.6. PubMed ID: 17868588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.